{"disease":{"id":"long-qt-syndrome-type-3","name":"long qt syndrome type 3"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07075445","title":"Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Thryv Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02300558","title":"Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}